
Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

A strong knowledge of pharmacology and clinical pharmacotherapeutics is essential for sports pharmacists, enabling them to support athletes' overall health while ensuring compliance with anti-doping regulations.

The pandemic showcased the resiliency and adaptability of pharmacists.

The study aims to assess how docosahexaenoic acid levels in cerebrospinal fluid relate to both neurodegeneration and cognitive function.

Results of the POETYK PsA-2 trial indicate deucravacitinib’s effectiveness at reducing the severity and burden of symptoms in patients with psoriatic arthritis.

Although improvements were observed in blood pressure (BP) medication adherence, there were no improvements in stain or glucose-lowering medication use.

Patients may have concerns about the boxed warning and other potential adverse effects associated with topical ruxolitinib for atopic dermatitis and vitiligo.


If approved, vutrisiran would be the first FDA-approved therapy to treat both the polyneuropathy and cardiomyopathy aspects of transthyretin amyloidosis (ATTR).

COVID-19 changed the personal and professional lives of all pharmacy workforce members. But what now?

AI can streamline biosimilar adoption by simplifying prescribing decisions and reducing costs.

The outbreak has grown to a total of 222 confirmed cases of measles, as well as 2 measles-associated deaths.

Pharmacists also navigate the REMS program and monitor and manage adverse effect profiles associated with bispecifics.

Sarcopenia, a progressive skeletal order that involves the accelerated loss of muscle mass and function, is associated with adverse outcomes such as functional decline, frailty, and mortality.

Michael McGuire, PharmD, highlights the importance of early intervention in hospital settings, leveraging manufacturer programs, and navigating complex dosing regimens.

The treatment is currently undergoing evaluation in an investigational preclinical program and is projected to be in human trials in 2026.

Policymakers and health care providers call for reforms to improve transparency, pricing, and patient access.

A brief period of overeating ultra-processed, high-calorie snacks could lead to liver fat accumulation and temporary disruption of brain insulin action.

Efficacy and tolerability of topical treatments can vary by region, particularly sensitive areas such as the face and neck.

Melatonin supplementation could improve oxidative DNA damage repair capacity among night shift workers.

The approval is based on results from 2 phase 3 clinical trials that showed revakinagene taroretcel’s efficacy in macular telangiectasia type 2 (MacTel).

The move is expected to expand clozapine access for patients with schizophrenia.

According to a news release, this marks the first significant innovation in epinephrine delivery for this patient population is more than 35 years.

Unlike other professionals such as nurses and physicians, pharmacists remain tethered to a fragmented state-by-state licensure model that creates unnecessary barriers to care.

Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.

Tezepelumab demonstrated efficacy compared with placebo when treating patients with chronic rhinosinusitis with nasal polyps.

The designation was granted after positive results from the phase 1 STOMP-I clinical trial (NCT01915927).

RSV vaccine acceptance among older adults is significantly influenced by perceived benefits.

The FDA is issuing new changes to labels on testosterone products, clarifying that there are no increases in major cardiac events among men with hypogonadism but noting an increase in blood pressure with the use of such products.